Model-Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time-Varying M Protein.

In conclusion, the current analysis demonstrates that Japanese ethnicity, prior line of therapy, time-varying M protein, and change in elotuzumab dosing regimen in cycle 19 have no clinically meaningful impact on elotuzumab pharmacokinetics and exposure in Japanese patients with multiple myeloma. PMID: 32656777 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32656777?dopt=Abstract

Source: The Journal of Clinical Pharmacology - July 11, 2020 Category: Drugs & Pharmacology Authors: Ide T, Roy A, Imai Y, Vezina HE Tags: J Clin Pharmacol Source Type: research